News | September 18, 2024
Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
He has been associated with Caplin Steriles Ltd., Mylan Laboratories Ltd., Caplin Point Laboratories Ltd., Strides Arcolab Ltd. and Novartis Vaccines and Diagnostics
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Total investment incurred for setting up the new R&D Rs 250 crore
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Subscribe To Our Newsletter & Stay Updated
